UnknownPhase 1NCT04660929
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Studying Adenocarcinoma of ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Carisma Therapeutics Inc
- Principal Investigator
- Jeanett WetzelCarisma Therapeutics
- Intervention
- CT-0508(biological)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (7)
- City of Hope National Medical Center, Duarte, California, United States
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- OHSU Knight Cancer Institute, Portland, Oregon, United States
- Abramson Cancer Center, Philadelphia, Pennsylvania, United States
- Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, United States
- M D Anderson Cancer Center, Houston, Texas, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04660929 on ClinicalTrials.govOther trials for Adenocarcinoma of ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07523529Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsBeijing Biotech
- RECRUITINGNCT07100288Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian CancerComplejo Hospitalario Universitario Insular Materno Infantil
- RECRUITINGPHASE2NCT06730347A Study of Lorigerlimab in Participants With Advanced Solid TumorsMacroGenics
- RECRUITINGPHASE1NCT06840886A Study of PHST001 in Advanced Solid TumorsPheast Therapeutics
- RECRUITINGPHASE2NCT05500391Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote MonitoringCentre Oscar Lambret
- RECRUITINGPHASE1, PHASE2NCT05922930Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE3NCT05601700Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)Ente Ospedaliero Ospedali Galliera
- ACTIVE NOT RECRUITINGPHASE2NCT05335993A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.CanariaBio Inc.